GMDA - Gamida Cell Ltd.
| Previous Close | 8.90 |
| Open | 9.79 |
| Bid | 0.00 x 1300 |
| Ask | 0.00 x 1300 |
| Day's Range | 8.64 - 9.79 |
| 52 Week Range | 7.99 - 15.41 |
| Volume | 6,950 |
| Avg. Volume | 16,014 |
| Market Cap | 223.152M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -10.53 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.00 |
- Business Wire•2 days ago
Gamida Cell to Present at the Solebury Trout Class of 2018 Biotech IPOs Investor Day
Gamida Cell Ltd. , a leading cellular and immune therapeutics company, today announced that Julian Adams, Ph.D., the company’s chief executive officer, will present an overview of the company at the Solebury Trout Class of 2018 Biotech IPOs Investor Day on Friday, April 26, 2019, at 2:30 p.m.
- Business Wire•19 days ago
Gamida Cell to Present at the 18th Annual Needham Healthcare Conference
Gamida Cell Ltd. , a leading cellular and immune therapeutics company, today announced that Julian Adams, Ph.D., the company’s chief executive officer, will present an overview of the company at the 18th Annual Needham Healthcare Conference on Tuesday, April 9, 2019, at 10:40 a.m.
- Business Wire•last month
Gamida Cell Nominates Two Healthcare Industry Veterans to Its Board of Directors
Gamida Cell Ltd. (GMDA), a leading cellular and immune therapeutics company, today announced the nominations of Shawn Cline Tomasello and Stephen T. Wills to its board of directors. If elected, Ms. Tomasello will join the compensation committee, and Mr. Wills will join the company’s audit committee, bringing commercial, operational and financial experience to Gamida Cell’s board of directors as the company advances its clinical development candidates: NiCord®, an investigational advanced cell therapy in Phase 3 clinical development designed to enhance and expand the life-saving benefits of hematopoietic stem cell (bone marrow) transplant, and NAM-NK, an investigational, cell-based cancer immunotherapy in Phase 1 development in patients with non-Hodgkin lymphoma and multiple myeloma.
- Zacks•last month
Gamida Cell Sees Hammer Chart Pattern: Time to Buy?
Gamida Cell Ltd. (GMDA) has been struggling lately, but the selling pressure may be coming to an end soon.
- Business Wire•2 months ago
Gamida Cell Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update
– Successfully Completed IPO Raising $53.2 Million in Gross Proceeds –
- Business Wire•2 months ago
Gamida Cell Announces Immune Reconstitution Data from Completed Phase 1/2 Clinical Study of NiCord® Presented at 2019 TCT Annual Meeting
Gamida Cell Ltd. (GMDA), a leading cellular and immune therapeutics company, today announced that translational data from the completed Phase 1/2 clinical study of NiCord® were reported in an oral presentation at the 2019 Transplantation & Cellular Therapy (TCT) Meetings of American Society for Blood and Marrow Transplantation (ASBMT) and Center for International Blood and Marrow Transplant Research (CIBMTR) in Houston, Texas. The data demonstrated that treatment with NiCord, an investigational advanced cell therapy designed to enhance and expand the life-saving benefits of bone marrow transplant for patients with hematologic malignancies, resulted in rapid and robust immune reconstitution. “Reconstitution of a patient’s bone marrow and immune system is a crucial factor in recovery following allogeneic hematopoietic stem cell transplant,” said Jaap-Jan Boelens, M.D., Ph.D., Chief, Pediatric Stem Cell Transplantation and Cellular Therapies Service, Memorial Sloan Kettering Cancer Center.
- Business Wire•2 months ago
Gamida Cell Presents New Data from Ongoing Phase 1 Study of NAM-NK and Initial Data from Phase 1/2 Study of NiCord® in Severe Aplastic Anemia at 2019 TCT Annual Meeting
Gamida Cell Ltd. (GMDA), a leading cellular and immune therapeutics company, today announced that new data from its NAM-NK and NiCord® programs was presented at the 2019 Transplantation & Cellular Therapy (TCT) Meetings of American Society for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research taking place in Houston, Texas. Data reported from the first 14 patients in the ongoing Phase 1 study of NAM-NK, an investigational, cell-based cancer immunotherapy, in patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) demonstrated that NAM-NK was highly active, with three complete responses observed in patients with NHL and one complete response in a patient with MM.
- Business Wire•2 months ago
Gamida Cell Announces Agreement with Editas Medicine to Evaluate Use of CRISPR Genome Editing Technology in NAM-NK Cells
Gamida Cell Ltd. (GMDA), a leading cellular and immune therapeutics company, today announced an agreement with Editas Medicine, Inc., a leading genome editing company, to evaluate the potential use of Editas Medicine’s CRISPR technology to edit NAM-NK cells, which are natural killer cells that have been expanded using Gamida Cell’s proprietary nicotinamide-based, or NAM, technology. Through this agreement, the companies aim to discover optimized NAM-NK cells that could be used to improve the treatment of hematologic malignancies (blood cancers) and solid tumors. “We are encouraged by the early data generated in the Phase 1 study of NAM-NK as an investigational therapy for patients with non-Hodgkin lymphoma and multiple myeloma, and we are pleased to have the opportunity to accelerate and broaden our NAM-NK research efforts through this agreement,” stated Julian Adams, Ph.D., chief executive officer of Gamida Cell.
- Business Wire•2 months ago
Gamida Cell to Host Conference Call and Webcast to Review Data from NAM-NK and NiCord® Programs Being Presented at 2019 TCT Annual Meeting
Gamida Cell Ltd. , a leading cellular and immune therapeutics company, today announced that it will host a conference call and webcast on Thursday, February 21, 2019, at 8:00 a.m.
- Business Wire•3 months ago
Gamida Cell Announces Data from NAM-NK and NiCord® Programs to Be Presented at 2019 TCT Annual Meeting
– Presentations include early data from Phase 1 study of NAM-NK in patients with non-Hodgkin lymphoma and multiple myeloma and data from NiCord® studies –
- Business Wire•3 months ago
Gamida Cell and Be The Match BioTherapies® Announce Strategic Collaboration
Gamida Cell Ltd. (GMDA), a leading cellular and immune therapeutics company, and Be The Match BioTherapies®, a subsidiary of the National Marrow Donor Program®/Be The Match® offering integrated platforms and software to manage the collection and delivery of cellular therapies, today announced a strategic collaboration to improve outcomes for patients undergoing allogeneic hematopoietic stem cell (bone marrow) transplantation. The collaboration supports NiCord®, Gamida Cell’s investigational cell therapy, which has the potential to serve as a universal bone marrow donor source for patients with hematologic malignancies, or blood cancers, and bone marrow failure disorders requiring bone marrow transplantation.
- Business Wire•4 months ago
Gamida Cell Announces 2019 Goals and Provides Company Update
Gamida Cell Ltd. (GMDA), a leading cellular and immune therapeutics company, reported expected milestones for 2019, which highlight the company’s progress advancing its clinical development candidates: NiCord®, an investigational universal bone marrow donor source in late-stage development for patients with hematologic malignancies (blood cancers), and NAM-NK, an investigational, cell-based cancer immunotherapy in development in patients with non-Hodgkin lymphoma and multiple myeloma.
- Business Wire•5 months ago
Gamida Cell Announces Publication of Phase 1/2 Clinical Data of NiCord® in the Journal of Clinical Oncology
Gamida Cell Ltd. (GMDA), a leading cellular and immune therapeutics company, today announced the publication of data from the previously reported, multi-center Phase 1/2 clinical study evaluating the safety and efficacy of NiCord® as a stand-alone, hematopoietic stem cell (bone marrow) transplant in the Journal of Clinical Oncology1,2. NiCord is an investigational product candidate in Phase 3 development as a universal bone marrow transplant solution for patients with high-risk hematologic malignancies, or blood cancers. Results from the Phase 1/2 study showed that patients transplanted with NiCord had rapid and durable engraftment of neutrophils and platelets, as well as prompt immune reconstitution.
- Business Wire•5 months ago
Gamida Cell Reports Immune Reconstitution Data from Completed Phase 1/2 Clinical Study of NiCord® Presented at ASH 2018 Annual Meeting
Gamida Cell Ltd. (GMDA), a leading cellular and immune therapeutics company, today reported translational data showing that recipients who received NiCord®, an investigational cell therapy in Phase 3 clinical development for allogeneic hematopoietic stem cell (bone marrow) transplant had rapid and robust reconstitution of key immune cells. Successful immune reconstitution is an important factor in the recovery of patients undergoing bone marrow transplant.
- Business Wire•5 months ago
Gamida Cell to Present at BMO Capital Markets Prescriptions for Success Healthcare Conference
Gamida Cell Ltd. , a leading cellular and immune therapeutics company, today announced that Julian Adams, Ph.D., the company’s chief executive officer, will participate in a fireside chat at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference on Wednesday, December 12th at 1:20 p.m.
- Business Wire•6 months ago
Gamida Cell Announces New Translational Data for Nicord® to Be Presented at ASH 2018 Annual Meeting
Gamida Cell Ltd. , a leading cellular and immune therapeutics company, today announced that new translational data for NiCord®, an investigational cell therapy in Phase 3 clinical development for allogeneic stem cell, or bone marrow, transplant, will be presented at the American Society of Hematology 2018 Annual Meeting, which is being held December 1-4 in San Diego, CA.
- Business Wire•6 months ago
Gamida Cell Announces Pricing of Initial Public Offering
Gamida Cell Ltd., a leading cellular and immune therapeutics company, today announced the pricing of its initial public offering of 6,250,000 ordinary shares at a public offering price of $8.00 per share for aggregate gross proceeds of $50.0 million. All of the shares in the offering are being offered by Gamida Cell. In addition, Gamida Cell granted the underwriters a 30-day option to purchase up to 937,500 additional ordinary shares at the initial offering price, less underwriting discounts and commissions.
- Investor's Business Daily•6 months ago
StoneCo IPO Soars As Trading Begins, Yeti IPO Falls Flat
Shares in the StoneCo IPO soared as trading began Thursday while the Yeti IPO fell, as the cooler company lowered the amount of shares offered.
- Investor's Business Daily•6 months ago
Brazil's StoneCo, Yeti Holdings Headline List Of IPOs This Week
IPOs this week are headlined by StoneCo, a Brazil-based payment processor that looks to raise $1 billion and Yeti Holdings, a maker of premium coolers.
